title: Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis.
abstract: Pergolide is a dopaminergic agonist used to treat Parkinson's disease but is associated with the development of retroperitoneal fibrosis (RPF). Newer nonergot agents (pramipexole, ropinirole) may not carry this same risk. A patient with a history of pergolide-induced RPF was treated successfully with ropinirole for 1 year without complications.
authors.affiliation: Clinical and Administrative Division, College of Pharmacy, University of Iowa, Iowa City 52242-1112, USA.
authors.forename: B C
authors.initials: BC
authors.lastname: Lund
authors.forename: R F
authors.initials: RF
authors.lastname: Neiman
authors.forename: P J
authors.initials: PJ
authors.lastname: Perry
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects* / Q000627:therapeutic use; D012185:Retroperitoneal Fibrosis / Q000139:chemically induced*
chemical_list: D000978:Antiparkinson Agents; D007211:Indoles; C046649:ropinirole; D010479:Pergolide